BMS Exercises its Option to Globally License Obsidian’s CD40L Cell Therapy

 BMS Exercises its Option to Globally License Obsidian’s CD40L Cell Therapy

BMS Exercises its Option to Globally License Obsidian’s CD40L Cell Therapy

Shots:

  • BMS has exercised its option to an exclusive WW license to a cell therapy based on Obsidian’s cytoDRiVE technology for the controlled expression of the immunomodulatory factor CD40L
  • In 2019, the companies collaborated to develop novel cell therapies, under which Obsidian is eligible to receive milestones and royalties on sales of therapies. Exercising the option marks BMS’ first opt in decision
  • Obsidian’s cytoDRiVE technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BMS

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post